For decades, Arieh Warshel, USC Distinguished Professor of Chemistry and a 2013 Nobel laureate, has used computer simulations ...
A couple struggling to access to a vital cancer treatment say they are are "extremely stressed" by the uncertainty in its ...
Saol Therapeutics received a complete response letter for its pyruvate dehydrogenase complex deficiency treatment a week ...
Jeff Schaffnit discusses Sanofi's advancements in BTK inhibitors and promising results for hemophilia A therapies at ASH 2025 ...
Immunotherapy has revolutionized cancer care by training the immune system to detect and destroy tumors. For many patients, ...
Axatilimab showed a consistent safety profile in cGVHD patients, with no new safety signals and a decrease in TEAEs over time. The AGAVE-201 trial led to FDA approval of axatilimab at 0.3 mg/kg every ...
Zacks Small Cap Research on MSN
CRDF: Initiating Coverage – Combination Therapy Elicits Superior Response
CRDF READ THE FULL CRDF RESEARCH REPORT We are initiating coverage of Cardiff Oncology, Inc. (NASDAQ:CRDF) with a valuation of $8.50 per share. This value is based on our estimates for successful ...
The field of dermatology has witnessed remarkable progress in the prevention and treatment of skin diseases over the past ...
Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its ...
A new phase 2 clinical trial suggests that a chemotherapy-free, minimal residual disease (MRD)–driven treatment strategy may offer durable remissions and the possibility of time-limited therapy for ...
A new wave of gene therapy treatments offer a new lease on life for people with inherited diseases such as haemophilia. But ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback